Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep 1:15:375-378.
doi: 10.2147/BTT.S317888. eCollection 2021.

Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection

Abdulaziz Madani  1 , Qais Almuhaideb  2
Affiliations
Case Reports

Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection

Abdulaziz Madani et al. Biologics. .

Abstract

Down syndrome is the most common chromosomal disorder and may present with a combination of dysmorphic features, congenital heart disease, and immunological deficiency. The association between Down syndrome and psoriasis is unclear. The prevalence of psoriasis in patients with Down syndrome ranges from 0.5% to 8%. The safety of biologics in the treatment of Down syndrome-related psoriasis is still debated. Down syndrome results in mild immunological abnormalities; consequently, the risk of infectious complications during immunosuppressive therapy might be higher in this group of patients. We report a case of a 33-year-old male, a case of chronic plaque psoriasis, Down syndrome (DS), asthma, and hepatitis B. The patient was started on Calcipotriene 0.005%-betamethasone 0.064% ointment, which failed to control the patient's psoriasis; thus, adalimumab was started. His response to adalimumab was significant, where over 70% improvement of the psoriatic lesions was seen.

Keywords: HBV; adalimumab; biologics; trisomy 21.

PubMed Disclaimer

Conflict of interest statement

The authors have received honoraria for serving as a speaker for AbbVie. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Extensive bilateral psoriatic lesions over the knee, anterior leg, and dorsum of the foot.
Figure 2
Figure 2
Significant improvement in psoriatic lesions after treatment with adalimumab.
See this image and copyright information in PMC

References

    1. Talamonti M, Galluzzo M, Chiricozzi A, et al. Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. J Drugs Dermatol. 2012;11(8):1000–1002. - PubMed
    1. Adamczyk M, Michalska-Jakubus M, Krasowska D. A 12-year-old girl with severe plaque psoriasis and Down syndrome treated successfully with etanercept. Acta Dermatovenerol Croat. 2017;25(2):155–158. - PubMed
    1. Patterson D. Molecular genetic analysis of Down syndrome. Hum Genet. 2009;126(1):195–214. doi:10.1007/s00439-009-0696-8 - DOI - PubMed
    1. Madan V, Williams J, Lear JT. Dermatological manifestations of Down’s syndrome. Clin Exp Dermatol. 2006;31(5):623–629. doi:10.1111/j.1365-2230.2006.02164.x - DOI - PubMed
    1. Marmon S, De Souza A, Strober BE. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatol Online J. 2012;18(6):13. doi:10.5070/D305M5F4BX - DOI - PubMed

Publication types

LinkOut - more resources